What top creators are saying about Abivax SA(ABVX)

The stock had fallen sharply, and the speaker noted competition from existing ulcerative colitis treatments and broader biotech volatility. No specific catalyst, timeline, or price target was provided.

The speaker was cautious about the uncertain, long investment horizon and the challenge of attracting investors amid biotech volatility and existing treatments for ulcerative colitis.

Described as a high-risk biotech whose shares had fallen amid sector sentiment and competition for investor capital; no specific catalyst or price target was discussed.

The company was presented as a long-horizon, sentiment-sensitive investment with potential treatments for Crohn's disease and ulcerative colitis, but it faces existing treatment competition.

A speaker expressed a favorable long-term view while emphasizing that investors would need to be very patient; no timeline, catalyst, or price target was given.

Martin liked Abivax as a long-term position and said it could be a good long requiring patience, though supporting company-specific details were not provided.

The speaker said he was long and liked the stock, despite its reported 26% year-to-date decline; no detailed thesis or target was provided.

Mentioned as a comparison for Spyre, without a specific valuation, trade, or price target.

A speaker said they were long and liked the company, while a possibly related comment noted a 26% year-to-date decline; the spoken company identification and thesis were uncertain.

Held as a speculative, high-volatility clinical biotech long play suitable for risk-tolerant portfolios.

Market is skeptical of buyout rumors due to lack of stock reaction and previous false starts.

Potential buyout candidate, but warned that betting on a buyout is reckless.

Significant momentum and high peak sales potential after resolving previous safety concerns.

Obefazimod shows best-in-disease efficacy in UC with safety data appearing within background ranges; potential M&A target.

High-conviction long-term hold; analyst remains 'all in' as the story unfolds.

Viewed as a 'dangerous' high-risk, high-reward play. The investment thesis is based on speculation that it is a likely M&A target with a potential buyout price of $150 or $200 per share.

The speaker is 'over the moon about' this stock, making it a high-conviction bullish pick.

The speaker is making a highly speculative bet by buying out-of-the-money call options based on rumors of a potential takeover by 'big pharma', hoping for a massive gain if an acquisition occurs at a high price like $200/share.

A very successful bullish call for the speaker, who calls it one of his 'favorite biotech picks' and expects the stock to hit 106.

Mentioned alongside Sarepta as a stock the speaker likes, indicating a bullish view.

The speaker is long the stock and identifies it as one of the 'big ones' with an upcoming binary event.

This is Martin Shkreli's specific long pick. He is very bullish due to his expertise in the sector and provides a specific price target of 200.

Mentioned briefly as a biotech stock the speaker likes and considers a 'long' position.

Very bullish view, described as a prime buyout/M&A target with a high likelihood of success. The stock is expected to 'keep steadily marching up' even without a buyout.

Mentioned briefly with a question about a potential earnings call, but with no further context, opinion, or analysis provided.

Mentioned as a past successful bullish call by the speaker to build credibility. No new or current investment insight was provided.

The speaker is very bullish and long, citing strong clinical data, trust in the CEO, and the belief that its drug will be a multi-billion dollar product.

The core thesis is that the company's drug could become 'one of the biggest drugs in pharmaceutical history' with potential for $5 billion in annual revenue, making it a 'no-brainer'.

Presented as a high-conviction long (buy) idea and potentially the speaker's 'biggest long.' It was directly recommended to a listener asking for a good stock to buy.

Mentioned as a past, successful long position. The speaker bought it as a 'momentum' trade after it had already risen significantly. The commentary is historical.

Speaker is extremely bullish, holds an oversized position, and believes the stock will go to at least $200, potentially $700, citing a talented CEO and a 'really, really nice product'.

Exceptionally bullish, called a 'great winner in biotech' with potential for a 10x return. The thesis is based on the potential of its science and the exceptional quality of its CEO, Mark de Garadeau.

Considered a long idea as the speaker holds a position, is happy with its performance, and stated, 'I like Abby Vax.'

The speaker's biggest long position with a price target of $200 or higher. The primary risk is the company's patent, but the speaker believes it will hold.

The speaker is very bullish, holding it as a large long position and viewing it as a potential acquisition target with a buyout price of $150-$170 per share.

The speaker holds a 'really big position' with high conviction due to what they believe is very strong data, stating 'I don't see how the stock can trade down.'